Madrigal Pharmaceuticals, Inc. (LON:0JXI)

London flag London · Delayed Price · Currency is GBP · Price in USD
502.93
+4.31 (0.86%)
At close: Jan 22, 2026
65.68%
Market Cap8.38B
Revenue (ttm)550.99M
Net Income (ttm)-215.09M
Shares Outn/a
EPS (ttm)-9.70
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2
Average Volume76
Open503.04
Previous Close498.62
Day's Range502.93 - 503.85
52-Week Range264.12 - 610.61
Beta-1.01
RSI37.56
Earnings DateFeb 25, 2026

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania. [Read more]

Industry Pharmaceutical Preparations
CEO William Sibold
Employees 528
Stock Exchange London Stock Exchange
Ticker Symbol 0JXI
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements